NovaMedica is a modern Russian pharmaceutical company established in 2012 by Domian Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica strategy is aimed at attraction into Russia of intellectual property rights for innovative pharmaceutical products and technologies as well as at development and implementation of own and contract R&D-projects.
NovaMedica owns intellectual property rights within Russia and the CIS for 36 innovations which are part of the portfolio of RusnanoMedInvest, venture capital foundation. NovaMedica pipline includes antivirus and anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases.
There is no newsletter category found.
Наш сайт использует файлы cookie для хранения данных.
Продолжая использовать сайт, вы даёте согласие на работу с этими файлами.